MISSION

Improving risk prediction for common diseases — to enable targeted screening and treatment, and reduce adverse events.

The risk of heart attack, diabetes, chronic kidney disease, and other common conditions can be assessed early in adulthood using genomics, family history, and routine clinical data. ARC-omix turns that prediction into a clinical-grade workflow that preventive and primary-care teams can use.

Dr. Iftikhar J. Kullo, MD — Founder & Principal Investigator

ABOUT US

OUR ORIGIN

ARC-omix was founded by Dr. Iftikhar J. Kullo, Professor of Medicine and Associate Director of the Mellowes Center for Genomic Sciences and Precision Medicine at the Medical College of Wisconsin, and one of the world’s leading authorities on polygenic risk scores. His work spans more than two decades developing and validating polygenic risk scores for a range of traits and diseases.

Dr. Kullo established one of the earliest preventive-genomics research programs at Mayo Clinic in 2002. In 2016, his lab conducted the MI-GENES randomized trial, returning polygenic risk results directly to primary-care patients, published in Circulation. He chairs the ClinGen Familial Hypercholesterolemia Variant Curation Expert Panel and serves as principal investigator on eMERGE and PRIMED.

The PRSMix ensemble methodology was developed and validated through the PRIMED Consortium. ARC-OMIX LLC is incorporated under a Medical College of Wisconsin license, and its clinical laboratory is structured for CLIA certification and CAP accreditation from the outset. All sequencing is performed by our partner lab. MCW’s Predictive Genomics Clinic, launched in April 2026, provides an active pilot site operating inside preventive-cardiology workflows.

Scientific background

Polygenic risk scoring builds on a century of quantitative genetics.

Quantitative genetics dates to Mendel’s inheritance experiments (1866) and Fisher’s polygenic model (1918), and advanced through genome-wide association studies, biobank-scale cohorts, and large meta-analyses. Polygenic risk scores bring this work into clinical practice; ARC-omix builds directly on the MI-GENES, PRIMED, and eMERGE research.

Principles

Principles guiding our approach.

Risk identified early can be acted on early

The highest-value moment in preventive medicine is before symptoms appear. Genetic risk information at 35 or 45 is far more actionable than a diagnosis at 60.

Clinical tools must meet clinical evidence standards

Polygenic risk has been validated in population studies with millions of participants. We do not offer a test unless the evidence supports it, and we do not present uncertainty as clarity.

Genetic risk tools must work across ancestries

Early polygenic tools were trained predominantly on European-ancestry populations, reducing their accuracy elsewhere. ARC-omix treats ancestry-calibrated training and validation as a non-negotiable design requirement, supporting broad applicability across ancestrally varied populations.

A test must fit the clinical workflow.

Many promising diagnostics failed to reach patients because they were too difficult to order, interpret, or act on. ARC-omix is designed to fit a 20-minute visit.

Advisors & collaborators

Built on established science and institutional partnerships.

Research consortia

Dr. Kullo serves as principal investigator on PRIMED and eMERGE — two of the largest multi-ancestry genomic research programs in the U.S. ARC-omix scores are calibrated against multi-ancestry reference populations exceeding 100,000 individuals.

Laboratory partner

Sequencing is performed by our partner lab, a CLIA-certified, CAP-accredited facility whose Blended Genome-Exome platform provides the sequencing infrastructure underlying every ARC-omix test.

Genetic counseling

ABGC-certified genetic counselors are available via telehealth for all patients and providers. Counseling is triggered automatically on monogenic-positive findings.

Have a question?

Email us at info@arc-omix.com, or fill out the form below and we’ll respond shortly.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.